Organization | Presbyterian/St. Luke's Medical Center, Denver

Presbyterian/St. Luke's Medical Center, Denver Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial

2005

NCT00114530

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2006

Timeline

NOW

Alternative names

Blood and Marrow Transplant Program, Colorado Blood Cancer Institute, Presbyterian/St. Luke's Medical Center, Denver | Blood and Marrow Transplant Program, Presbyterian/St. Luke's Medical Center, Rocky Mountain Cancer Center

Active Ingredients

Drugs in Phase 3 Trials (5)

autologous mononuclear stem cell (1 trial)

cyclophosphamide (cytoxan) (1 trial)

lymphocyte immune globulin, anti-thymocyte globulin (equine) (Atgam) (1 trial)

methylprednisolone (medrol) (1 trial)

sargramostim (leukine) (2 trials)

Drugs in Phase 2 Trials (6)

autologous hematopoietic cell (1 trial)

carmustine (bicnu) (1 trial)

cytarabine (cytosar-u) (1 trial)

etoposide (vepesid) (1 trial)

melphalan (alkeran) (1 trial)

prednisone (meticorten) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Autoimmune Diseases (Phase 3)

Multiple Sclerosis (Phase 2)

Multiple Sclerosis, Relapsing-Remitting (Phase 2)

Scleroderma, Diffuse (Phase 3)

Scleroderma, Systemic (Phase 3)

Sclerosis (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 2
# of Trial APIs: 11